J&J Innovative Medicine

Check out this infographic breakdown of the company’s second-quarter performance, with highlights from its Innovative Medicine and MedTech businesses.

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.

Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy.

Diagnosed with systemic lupus erythematosus (SLE) almost two decades ago, Laurie Bean has chosen a lifestyle that helps her battle debilitating side effects and the emotional fallout of this autoantibody disease.

Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. Learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.

Johnson & Johnson’s Leonardo Diaz, M.D., addresses common misconceptions about schizophrenia, the critical importance of preventing relapse and why there’s so much optimism about treatments.

Check out this infographic breakdown of the company’s first-quarter performance, with highlights from its Innovative Medicine and MedTech businesses.